Metacrine, Inc. logo

MTCR - Metacrine, Inc. Share Price

$3.95 0.2  6.2%

Last Trade - 3:55pm

Small Cap
Market Cap £70.0m
Enterprise Value £7.67m
Revenue £n/a
Position in Universe 5148th / 6852
Unlock MTCR Revenue
Relative Strength (%)
1m -56.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -77.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 1.45 1.45 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Metacrine Inc revenues was not reported. Net loss increased29% to $37.3M. Higher net loss reflects General andadministrative - Balancin increase from $2.9M to $6.1M(expense), Stock-based Compensation in SGA increase from$1.1M to $3.8M (expense), Interest income decrease of 65%to $494K (income). Basic Earnings per Share excludingExtraordinary Items decreased from -$1.12 to -$1.44.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MTCR Revenue Unlock MTCR Revenue

Net Income

MTCR Net Income Unlock MTCR Revenue

Normalised EPS

MTCR Normalised EPS Unlock MTCR Revenue

PE Ratio Range

MTCR PE Ratio Range Unlock MTCR Revenue

Dividend Yield Range

MTCR Dividend Yield Range Unlock MTCR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MTCR EPS Forecasts Unlock MTCR Revenue
Profile Summary

Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
No. of Shareholders: 92
No. of Employees: 35
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 26,209,327
Free Float (0.0%)
Eligible for
MTCR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MTCR
Upcoming Events for MTCR
Monday 24th May, 2021
Metacrine, Inc. Annual Shareholders Meeting
Frequently Asked Questions for Metacrine, Inc.
What is the Metacrine, Inc. share price?

As of 3:55pm, shares in Metacrine, Inc. are trading at $3.95, giving the company a market capitalisation of £70.0m. This share price information is delayed by 15 minutes.

How has the Metacrine, Inc. share price performed this year?

Shares in Metacrine, Inc. are currently trading at $3.95 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Metacrine, Inc. price has moved by % over the past year.

What are the analyst and broker recommendations for Metacrine, Inc.?

There are no analysts currently covering Metacrine, Inc..

When will Metacrine, Inc. next release its financial results?

Metacrine, Inc. is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Metacrine, Inc. dividend yield?

Metacrine, Inc. does not currently pay a dividend.

Does Metacrine, Inc. pay a dividend?

Metacrine, Inc. does not currently pay a dividend.

When does Metacrine, Inc. next pay dividends?

Metacrine, Inc. does not currently pay a dividend.

How do I buy Metacrine, Inc. shares?

To buy shares in Metacrine, Inc. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Metacrine, Inc.?

Shares in Metacrine, Inc. are currently trading at $3.95, giving the company a market capitalisation of £70.0m.

Where are Metacrine, Inc. shares listed? Where are Metacrine, Inc. shares listed?

Here are the trading details for Metacrine, Inc.:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: MTCR
What kind of share is Metacrine, Inc.?

Based on an overall assessment of its quality, value and momentum, Metacrine, Inc. is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Metacrine, Inc. share price forecast 2021?

Shares in Metacrine, Inc. are currently priced at $3.95. At that level they are trading at 0.451% discount to the analyst consensus target price of 0.00.

Analysts covering Metacrine, Inc. currently have a consensus Earnings Per Share (EPS) forecast of -2.232 for the next financial year.

How can I tell whether the Metacrine, Inc. share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Metacrine, Inc.. Over the past six months, the relative strength of its shares against the market has been -65.6%. At the current price of $3.95, shares in Metacrine, Inc. are trading at -57.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Metacrine, Inc. PE Ratio?

We were not able to find PE ratio data for Metacrine, Inc..

Who are the key directors of Metacrine, Inc.?

Metacrine, Inc.'s management team is headed by:

Trisha Millican - CFO
Nicholas Smith - SVP
Eric Bischoff - VOP
Preston Klassen - PRE
Richard Heyman - CHM
Jeffrey Jonker - IND
Kristina Burow - IND
Julia Owens - IND
Who are the major shareholders of Metacrine, Inc.?

Here are the top five shareholders of Metacrine, Inc. based on the size of their shareholding:

New Enterprise Associates (NEA) Venture Capital
Percentage owned: 11.69% (3.06m shares)
VenBio Partners LLC Private Equity
Percentage owned: 11.67% (3.06m shares)
ARCH Venture Partners Venture Capital
Percentage owned: 11.22% (2.94m shares)
Polaris Partners Corporation
Percentage owned: 11.04% (2.89m shares)
Alexandria Venture Investments LLC Corporation
Percentage owned: 4.99% (1.31m shares)
Similar to MTCR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.